Aldeyra Therapeutics Announces Executive Team Changes
Company Announcements

Aldeyra Therapeutics Announces Executive Team Changes

An update from Aldeyra Therapeutics (ALDX) is now available.

Aldeyra Therapeutics, Inc. has announced the appointment of Michael Alfieri as the new principal financial officer and principal accounting officer, effective August 31, 2024. Alfieri, who brings extensive experience from previous roles in biopharmaceutical companies like Genocea Biosciences and Radius Health, will operate under a consulting agreement through Danforth Global, Inc. Concurrently, Bruce Greenberg will depart from his executive roles at Aldeyra and has agreed to a separation package which includes salary continuation, a lump-sum payment, and consulting services that allow for the vesting of his stock options.

For an in-depth examination of ALDX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAldeyra resubmits topical ocular reproxalap NDA to FDA
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App